Canagliflozin and Xeljanz drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 52 people who take Canagliflozin and Xeljanz. Common interactions include drug hypersensitivity among females, and drug ineffective among males.

The phase IV clinical study analyzes what interactions people who take Canagliflozin and Xeljanz have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

52 people who take Canagliflozin and Xeljanz together, and have interactions are studied.

What is Canagliflozin?

Canagliflozin has active ingredients of canagliflozin. Currently, eHealthMe is studying from 2,869 Canagliflozin users.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is used in rheumatoid arthritis. Currently, eHealthMe is studying from 222,436 Xeljanz users.

Number of Canagliflozin and Xeljanz reports submitted per year:

Canagliflozin and Xeljanz drug interactions.

Common Canagliflozin and Xeljanz drug interactions by gender *:


  1. Drug hypersensitivity
  2. Drug ineffective
  3. Postoperative wound infection
  4. Arthralgia
  5. Blood pressure diastolic increased
  6. Blood pressure fluctuation
  7. Chest pain
  8. Flushing
  9. Heart rate irregular
  10. Hypertension


  1. Drug ineffective
  2. Abdominal discomfort
  3. Dyspepsia
  4. Gastrointestinal infection
  5. Hand deformity
  6. Hepatic cirrhosis
  7. Hepatic fibrosis
  8. Hepatic steatosis
  9. Hypertension
  10. Infection

Common Canagliflozin and Xeljanz drug interactions by age *:












  1. Blood pressure diastolic increased
  2. Blood pressure fluctuation
  3. Drug hypersensitivity
  4. Drug ineffective
  5. Flushing
  6. Heart rate irregular
  7. Hypertension
  8. Oropharyngeal discomfort
  9. Pneumonia
  10. Tachycardia


  1. Abdominal discomfort
  2. Alanine aminotransferase increased
  3. Anti-cyclic citrullinated peptide antibody positive
  4. Arthralgia
  5. Arthropathy
  6. Bone cyst
  7. Bone erosion
  8. C-reactive protein increased
  9. Diabetes mellitus
  10. Diarrhoea


  1. Drug ineffective
  2. Musculoskeletal stiffness
  3. Drug intolerance
  4. Drug-induced liver injury
  5. Dyspepsia
  6. Gastrointestinal infection
  7. Hand deformity
  8. Hepatic cirrhosis
  9. Hepatic fibrosis
  10. Hepatic steatosis

Common conditions people have *:

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 45 people, 86.54%
  2. Psoriasis (immune-mediated disease that affects the skin): 44 people, 84.62%

* Approximation only. Some reports may have incomplete information.

Do you take Canagliflozin and Xeljanz?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Canagliflozin drug interactions:

Browse interactions between Canagliflozin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Xeljanz drug interactions:

Browse interactions between Xeljanz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on canagliflozin and tofacitinib citrate (the active ingredients of Canagliflozin and Xeljanz, respectively), and Canagliflozin and Xeljanz (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Canagliflozin and Xeljanz.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: